Switching COPD patients from the disposable to the new reusable Respimat soft mist inhaler: a real-world study from Switzerland. (2nd November 2021)

• Record Type: Journal Article
• Authors: Tschacher, Anne; Cadus, Cordula; Schildge, Sebastian; Diedrich, Jens Peter; Chhajed, Prashant N.; Leuppi-Taegtmeyer, Anne B.; Leuppi, Jörg Daniel
• Is Part Of: Current medical research and opinion. Volume 37:Number 11(2021)
• Page Start: 2019
• Page End: 2033
• Publication Date: 2021-11-02
• Subjects: Reusable Respimat inhaler -- COPD -- patient´s satisfaction -- placebo inhaler; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2021.1969354
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: The aims of the survey were to assess first experiences of Swiss COPD patients switching from the disposable to the new reusable Respimat inhaler, and to evaluate physicians´ and patients´ views of the new training material. Methods: Patients with a confirmed diagnosis of COPD using a disposable Respimat inhaler for at least three months were included. Patients´ demographics, COPD stage, current treatment, and comorbidities relevant for the handling of the device were assessed. Further, patients were trained on the reusable Respimat by placebo inhaler, patient brochure, video cards/demo films and SMS reminder service. After at least one cartridge change, patients gave comprehensive feedback on their satisfaction with the reusable Respimat and physicians evaluated the need for re-training. Results: 235 patients participated in the survey. Of these, 37% suffered from comorbidities restricting the handling of the Respimat. 216 (92%) patients had a better overall satisfaction with the reusable than with the disposable Respimat. Dose counter (86%), monthly preparation (81%) and daily handling (77%) were also assessed as better by most of the patients. In 80% of cases, the user ability was stated as better than for the disposable Respimat. Less than 15% of the patients required further training. Placebo inhaler was the mostly preferred training material by both, physicians (in 86% of the patients) and patients (75%). In patients with comorbidities affecting inhaler handling, overall satisfaction was also better in 86% of the patients. Conclusion: The majority of patients were satisfied with the new reusable Respimat device and proper handling could be attained using the provided training material, even in patients with restricting comorbidities.